Flagship Harbor Advisors LLC Has $732,000 Position in Bristol-Myers Squibb Company (BMY)
Flagship Harbor Advisors LLC decreased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 3.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,962 shares of the biopharmaceutical company’s stock after selling 408 shares during the period. Flagship Harbor Advisors LLC’s holdings in Bristol-Myers Squibb were worth $732,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Blue Chip Partners Inc. boosted its stake in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Keel Point LLC boosted its stake in Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 18 shares in the last quarter. Staley Capital Advisers Inc. boosted its stake in Bristol-Myers Squibb by 0.3% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after purchasing an additional 24 shares in the last quarter. Shayne & CO. LLC boosted its stake in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 24 shares in the last quarter. Finally, Chilton Investment Co. LLC boosted its stake in Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares in the last quarter. Institutional investors own 68.97% of the company’s stock.
A number of equities analysts have weighed in on BMY shares. Barclays PLC boosted their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Jefferies Group LLC lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price for the company. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Leerink Swann boosted their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Citigroup Inc. boosted their target price on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $64.93.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Flagship Harbor Advisors LLC Has $732,000 Position in Bristol-Myers Squibb Company (BMY)” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/flagship-harbor-advisors-llc-has-732000-position-in-bristol-myers-squibb-company-bmy/1718927.html.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.24 on Wednesday. The stock has a market cap of $99,511.36, a P/E ratio of 20.54, a P/E/G ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.77 earnings per share. analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.55%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.